JPH11507033A - トロンボポイエチンを精製する方法 - Google Patents
トロンボポイエチンを精製する方法Info
- Publication number
- JPH11507033A JPH11507033A JP9500670A JP50067097A JPH11507033A JP H11507033 A JPH11507033 A JP H11507033A JP 9500670 A JP9500670 A JP 9500670A JP 50067097 A JP50067097 A JP 50067097A JP H11507033 A JPH11507033 A JP H11507033A
- Authority
- JP
- Japan
- Prior art keywords
- tpo
- thrombopoietin
- exchange chromatography
- hydroxyapatite
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000036693 Thrombopoietin Human genes 0.000 title claims abstract description 112
- 108010041111 Thrombopoietin Proteins 0.000 title claims abstract description 112
- 238000000034 method Methods 0.000 title claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims abstract description 29
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims abstract description 29
- 239000000356 contaminant Substances 0.000 claims abstract description 26
- 239000003446 ligand Substances 0.000 claims abstract description 18
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 18
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 17
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 16
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 10
- 239000013060 biological fluid Substances 0.000 claims description 16
- 238000005571 anion exchange chromatography Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000005277 cation exchange chromatography Methods 0.000 claims description 10
- 239000003636 conditioned culture medium Substances 0.000 claims description 9
- 238000005194 fractionation Methods 0.000 claims description 8
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 claims description 7
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 claims description 7
- 239000011324 bead Substances 0.000 claims description 7
- 230000001143 conditioned effect Effects 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 6
- 102000053400 human TPO Human genes 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229920002401 polyacrylamide Polymers 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- -1 sulfopropyl group Chemical group 0.000 claims description 3
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 238000011109 contamination Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 4
- 238000001556 precipitation Methods 0.000 abstract description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 210000001185 bone marrow Anatomy 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000001632 sodium acetate Substances 0.000 description 7
- 235000017281 sodium acetate Nutrition 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 102000003951 Erythropoietin Human genes 0.000 description 6
- 108090000394 Erythropoietin Proteins 0.000 description 6
- 238000011026 diafiltration Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229940105423 erythropoietin Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- 206010043554 thrombocytopenia Diseases 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 108010002386 Interleukin-3 Proteins 0.000 description 5
- 102000000646 Interleukin-3 Human genes 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 102000003815 Interleukin-11 Human genes 0.000 description 3
- 108090000177 Interleukin-11 Proteins 0.000 description 3
- 208000013544 Platelet disease Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 229940047120 colony stimulating factors Drugs 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 206010033661 Pancytopenia Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000035921 thrombopoiesis Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241001214445 Mimetes Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000694108 Mus musculus Thyroid peroxidase Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 102000054764 human MPL Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 230000003343 megakaryocytopoietic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.生物学的液体からトロンボポイエチン(TPO)を精製する方法であって、 リガンドアフィニティクロマトグラフィー、イオン交換クロマトグラフィー、 疎水性相互作用クロマトグラフィー及び限外ろ過からなる群から選択された方法 により、TPO−含有生物学的液体の容積を減少させて濃縮された画分をもたらし 、 前記濃縮された画分の塩濃度を調整して、調整された溶液をもたらし、 前記調整された溶液を酸性化して、汚染物質タンパク質を沈殿させ、透明な溶 液をもたらし、 前記透明な溶液をアニオン交換クロマトグラフィーにより分別して、TPOを豊 富化させた画分をもたらし、 前記 TPOを豊富化させた画分をヒドロキシアパタイトに暴露させ、それにより タンパク質汚染物質は前記ヒドロキシアパタイトに結合し、TPOは実質的に結合 してないままであり、 前記結合していない TPOを捕集し、そして、 前記捕集した TPOをカチオン交換クロマトグラフィーまたは限外ろ過により濃 縮することを含む前記方法。 2.前記生物学的液体が細胞順化培地またはそれらの部分である請求項1に記 載の方法。 3.前記 TPOがヒト TPOである請求項1に記載の方法。 4.前記減少させる工程が染料−リガンドアフィニティクロマトグラフィーに よる直接捕獲を含む請求項1に記載の方法。 5.前記減少させる工程が誘導体化、架橋アガロースビーズのマトリックス上 の直接捕獲を含む請求項4に記載の方法。 6.前記調整工程が限外ろ過を含む請求項1に記載の方法。 7.前記濃縮工程がカチオン交換クロマトグラフィーを含む請求項1に記載の 方法。 8.前記濃縮工程がスルホプロピル基を用いて誘導体化された不溶性支持体を 用いるものである請求項7に記載の方法。 9.前記分別工程がアニオン交換クロマトグラフィーを含む請求項1に記載の 方法。 10.前記分別工程がトリメチルアミノエチル基を用いて誘導体化された不溶性 支持体を用いるものである請求項9に記載の方法。 11.前記捕集された TPOの分子量が、変性条件下の SDS−ポリアクリルアミド ゲル電気泳動により測定して、70,000±10,000ダルトンである請求項1に記載の 方法。 12.前記タンパク質汚染物質がトロンボポイエチンの凝集物を含む請求項1に 記載の方法。 13.生物学的液体からトロンボポイエチン(TPO)を精製する方法であって、 TPO含有生物学的液体の容積を、染料−リガンドアフィニティクロマトグラフ ィーによる直接捕獲により減少させて、濃縮画分をもたらし、 前記濃縮された画分中の塩濃度を限外ろ過により調整して、調整された溶液を もたらし、 前記調整された溶液をアニオン交換クロマトグラフィーによって分別して、TP Oを豊富化された画分をもたらし、 前記 TPOを豊富化された画分をヒドロキシアパタイトに暴露し、それによりタ ンパク質汚染物質をヒドロキシアパタイトに結合させ、そして TPOは溶出させ、 前記溶出された TPOをカチオン交換クロマトグラフィーにより濃 縮する方法。 14.トロンボポイエチン及びタンパク質汚染物質を含む溶液からタンパク質汚 染物質を除去する方法であって、前記溶液をヒドロキシアパタイトに暴露させ、 それにより前記タンパク質汚染物質は前記ヒドロキシアパタイトに結合し、前記 トロンボポイエチンは実質的に結合しないままであり、そして、結合していない トロンボポイエチンを回収することを含む前記方法。 15.前記タンパク質汚染物質がトロンボポイエチンの凝集物を含む請求項14記 載の方法。 16.トロンボポイエチン含有液体組成物をイオン交換クロマトグラフィー、リ ガンドアフィニティクロマトグラフィーまたは疎水性相互作用イオンクロマトグ ラフィーによる分別することにより、前記溶液を調製する請求項14に記載の方法 。 17.前記溶液をトロンボポイエチン含有液体組成物のアニオン交換クロマトグ ラフィーによる分別により調製する請求項16に記載の方法。 18.前記溶液をトロンボポイエチン含有液体組成物のアニオン交換クロマトグ ラフィー及びリガンドアフィニティクロマトグラフィーの組合せによる分別によ り調製する請求項16に記載の方法。 19.前記回収されたトロンボポイエチンをカチオン交換クロマトグラフィーま たは限外ろ過により濃縮する請求項14に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/484,246 US5744587A (en) | 1995-06-07 | 1995-06-07 | Method for purifying thrombopoietin |
US08/484,246 | 1995-06-07 | ||
PCT/US1996/007453 WO1996040773A1 (en) | 1995-06-07 | 1996-05-22 | Method for purifying thrombopoietin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11507033A true JPH11507033A (ja) | 1999-06-22 |
Family
ID=23923351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9500670A Ceased JPH11507033A (ja) | 1995-06-07 | 1996-05-22 | トロンボポイエチンを精製する方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5744587A (ja) |
EP (1) | EP0839158B1 (ja) |
JP (1) | JPH11507033A (ja) |
KR (1) | KR100255466B1 (ja) |
AT (1) | ATE314391T1 (ja) |
AU (1) | AU694043B2 (ja) |
CA (1) | CA2223236C (ja) |
DE (1) | DE69635661T2 (ja) |
MX (1) | MX9709312A (ja) |
NZ (1) | NZ308862A (ja) |
WO (1) | WO1996040773A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010104365A (ja) * | 2008-09-30 | 2010-05-13 | Denka Seiken Co Ltd | 精製インフルエンザウイルス抗原の製造方法 |
JP2014507368A (ja) * | 2011-02-02 | 2014-03-27 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | アルカリ溶液でのアパタイトの表面中和方法 |
JPWO2021186750A1 (ja) * | 2020-03-17 | 2021-09-23 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6414123B1 (en) * | 1997-10-21 | 2002-07-02 | Vitro Diagnostics, Inc. | Method for purifying FSH |
US20020168632A1 (en) * | 1998-02-06 | 2002-11-14 | Narang Harash Kumar | Monitoring of liquids for disease-associated materials |
US6589759B1 (en) | 1999-03-30 | 2003-07-08 | Trustees Of Boston University | Compositions and methods for producing platelets and/or proplatelets from megakaryocytes |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
ES2275737T3 (es) | 2000-09-29 | 2007-06-16 | Cordis Corporation | Dispositivos medicos revestidos. |
EP1463942B2 (en) * | 2001-12-21 | 2012-06-20 | Immunex Corporation | Methods for purifying protein |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
US20070264710A1 (en) * | 2003-10-09 | 2007-11-15 | Hyea-Kyung Ahn | Process for Purifying Human Thrombopoietin with High Content of Sialic Acid |
DE102004027816A1 (de) * | 2004-06-08 | 2006-01-05 | Bioceuticals Arzneimittel Ag | Verfahren zur Reinigung von Erythropoietin |
US7879318B2 (en) * | 2006-01-23 | 2011-02-01 | Mcw Research Foundation, Inc. | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand |
CA2787009C (en) * | 2010-01-15 | 2018-04-03 | Bio-Rad Laboratories, Inc. | Surface neutralization of apatite |
US8895707B2 (en) | 2010-08-18 | 2014-11-25 | Bio-Rad Laboratories, Inc. | Elution of proteins from hydroxyapatite resins without resin deterioration |
CN104507952B (zh) | 2012-05-30 | 2018-08-10 | 生物辐射实验室股份有限公司 | 基于磷灰石的色谱树脂的原位恢复 |
EP3157863B1 (en) | 2014-06-23 | 2023-06-21 | Bio-Rad Laboratories, Inc. | Apatite in-situ restoration |
CN105392569B (zh) | 2014-06-23 | 2019-08-20 | 生物辐射实验室股份有限公司 | 磷灰石预处理 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5128449A (en) * | 1988-07-05 | 1992-07-07 | The University Of Tennessee Research Corporation | Polypeptide and a method for its production |
SG79882A1 (en) * | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
US5571686A (en) * | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
-
1995
- 1995-06-07 US US08/484,246 patent/US5744587A/en not_active Expired - Fee Related
-
1996
- 1996-05-22 AU AU58718/96A patent/AU694043B2/en not_active Ceased
- 1996-05-22 NZ NZ308862A patent/NZ308862A/xx unknown
- 1996-05-22 CA CA002223236A patent/CA2223236C/en not_active Expired - Fee Related
- 1996-05-22 AT AT96920393T patent/ATE314391T1/de not_active IP Right Cessation
- 1996-05-22 KR KR1019970709022A patent/KR100255466B1/ko not_active IP Right Cessation
- 1996-05-22 DE DE69635661T patent/DE69635661T2/de not_active Expired - Fee Related
- 1996-05-22 WO PCT/US1996/007453 patent/WO1996040773A1/en active IP Right Grant
- 1996-05-22 JP JP9500670A patent/JPH11507033A/ja not_active Ceased
- 1996-05-22 EP EP96920393A patent/EP0839158B1/en not_active Expired - Lifetime
- 1996-05-22 MX MX9709312A patent/MX9709312A/es not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010104365A (ja) * | 2008-09-30 | 2010-05-13 | Denka Seiken Co Ltd | 精製インフルエンザウイルス抗原の製造方法 |
JP2014507368A (ja) * | 2011-02-02 | 2014-03-27 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | アルカリ溶液でのアパタイトの表面中和方法 |
JPWO2021186750A1 (ja) * | 2020-03-17 | 2021-09-23 |
Also Published As
Publication number | Publication date |
---|---|
ATE314391T1 (de) | 2006-01-15 |
KR100255466B1 (ko) | 2000-05-01 |
MX9709312A (es) | 1998-02-28 |
CA2223236C (en) | 2000-09-19 |
CA2223236A1 (en) | 1996-12-19 |
DE69635661D1 (de) | 2006-02-02 |
EP0839158A1 (en) | 1998-05-06 |
WO1996040773A1 (en) | 1996-12-19 |
AU5871896A (en) | 1996-12-30 |
US5744587A (en) | 1998-04-28 |
EP0839158B1 (en) | 2005-12-28 |
DE69635661T2 (de) | 2006-07-20 |
KR19990022541A (ko) | 1999-03-25 |
AU694043B2 (en) | 1998-07-09 |
NZ308862A (en) | 1999-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11507033A (ja) | トロンボポイエチンを精製する方法 | |
CA1120468A (en) | Hgi-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same | |
JPH07503851A (ja) | 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法 | |
CA1188244A (en) | Angiotropins of leukocytes and inflamed tissue and process for their preparation | |
MXPA97009312A (en) | Method for purifying trombopoyet | |
EP0276551B1 (en) | Colony-stimulating factor and method for preparation thereof | |
KR20040071212A (ko) | 생물학적 활성 과립구 콜로니 자극 인자의 정제 및(또는)단리 방법 | |
US5853714A (en) | Method for purification of IL-12 | |
CN103153333A (zh) | 补体因子h的纯化方法 | |
KR0131204B1 (ko) | 암 면역치료용 보조제 | |
CA1283048C (en) | Therapeutic agent for treating hematopoietic diseases | |
JP2580391B2 (ja) | インタロイキン―4の精製法 | |
JP3014099B2 (ja) | 生物的材料、生物的材料の生産およびこの種の材料の治療への使用方法 | |
WO1992001002A1 (fr) | Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation | |
EP0328132B1 (en) | Therapeutic agent for thrombocytopenia | |
WO2011024024A1 (en) | A process for recovering darbepoeitin alfa isoforms | |
US5034133A (en) | Purification of human interleukin-4 from a CHO-cell line culture medium | |
CA1336679C (en) | Remedy for hematopoietic tissue diseases comprising human monocytic macrophage colony stimulating factor as active ingredient | |
AU746411B2 (en) | Preparation of glycosylated tumor necrosis factor | |
JP2007528195A (ja) | 高シアル酸含量のヒトトロンボポエチンを精製する方法 | |
JPH06192124A (ja) | 血液細胞増加剤 | |
JPS62169799A (ja) | マクロフア−ジ分化増殖促進物質 | |
JPH07118163A (ja) | β2−ミクログロブリンを含有する組成物 | |
JPS62149624A (ja) | 巨核球・血小板系増加剤 | |
JPS62108818A (ja) | 新規蛋白性物質の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050705 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051004 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051114 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20060220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060328 |